UBS Lowers Price Target for Scotts Miracle Gro to $68 Amid Neutral Rating
ByAinvest
Thursday, Jul 31, 2025 5:29 pm ET1min read
JFU--
The latest move by UBS comes on the heels of several recent analyst ratings and price target adjustments for SMG. In July 2025, Truist Securities maintained a "Buy" rating and raised the price target from $75.00 to $80.00, a 6.67% increase [2]. Wells Fargo also maintained an "Overweight" rating and raised the price target from $72.00 to $75.00, a 4.17% increase [2].
Based on the one-year price targets offered by six analysts, the average target price for SMG is $76.33, with a high estimate of $82.00 and a low estimate of $71.00. This average target implies an upside of 24.63% from the current price of $61.25 [1]. The average brokerage recommendation from 10 firms is 2.2, indicating an "Outperform" status [1].
GuruFocus estimates the GF Value for SMG in one year to be $59.83, suggesting a downside of 2.32% from the current price of $61.25 [1]. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at, calculated based on historical multiples and future performance estimates.
References:
[1] https://www.gurufocus.com/news/3022956/ubs-maintains-neutral-rating-on-smg-but-lowers-price-target-to-68-smg-stock-news
[2] https://www.marketscreener.com/news/scotts-miracle-gro-earnings-call-transcript-smg-usq-transcript-2025-07-30-ce7c5fddd189f62d
SMG--
WFC--
UBS analyst Peter Grom maintains a "Neutral" rating for Scotts Miracle Gro (SMG) but lowers the price target from $71 to $68, a 4.23% decrease. This reflects a cautious stance on the stock amid current market conditions. The average one-year price target from six analysts is $76.33, with an upside of 24.63% from the current price of $61.25. The average brokerage recommendation is 2.2, indicating "Outperform" status. The estimated GF Value in one year is $59.83, suggesting a downside of 2.32% from the current price.
UBS analyst Peter Grom has maintained a "Neutral" rating for Scotts Miracle-Gro (SMG), while lowering the price target from $71.00 to $68.00. This adjustment represents a 4.23% decrease from the previous target, reflecting a cautious stance on the stock amid current market conditions [1].The latest move by UBS comes on the heels of several recent analyst ratings and price target adjustments for SMG. In July 2025, Truist Securities maintained a "Buy" rating and raised the price target from $75.00 to $80.00, a 6.67% increase [2]. Wells Fargo also maintained an "Overweight" rating and raised the price target from $72.00 to $75.00, a 4.17% increase [2].
Based on the one-year price targets offered by six analysts, the average target price for SMG is $76.33, with a high estimate of $82.00 and a low estimate of $71.00. This average target implies an upside of 24.63% from the current price of $61.25 [1]. The average brokerage recommendation from 10 firms is 2.2, indicating an "Outperform" status [1].
GuruFocus estimates the GF Value for SMG in one year to be $59.83, suggesting a downside of 2.32% from the current price of $61.25 [1]. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at, calculated based on historical multiples and future performance estimates.
References:
[1] https://www.gurufocus.com/news/3022956/ubs-maintains-neutral-rating-on-smg-but-lowers-price-target-to-68-smg-stock-news
[2] https://www.marketscreener.com/news/scotts-miracle-gro-earnings-call-transcript-smg-usq-transcript-2025-07-30-ce7c5fddd189f62d

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet